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eratoconus typically has its onset at puberty and progresses until the third to fourth decade of life, when it usually stabilizes. 1 Ertan and Muftuoglu 2 observed almost 10 times more keratoconic eyes with a higher rate of severe disease in younger patients (aged р40 years) than in older patients (Ͼ40 years); they also reported that the severity of keratoconus is inversely correlated to age. The technique of corneal collagen cross-linking (CXL), 3 conceived in Dresden, Germany, 4 consists of a photopolymerization of stromal collagen fi bers induced by the combined action of a photosensitizing substance (ribofl avin or vitamin B2) and ultraviolet A (UVA) light. Cross-linking induces corneal stiffening by increasing the number of intra-and interfibrillar covalent bonds and corneal collagen resistance against enzymatic degradation. 5, 6 Because ribofl avin is a hydrophilic compound and cannot easily cross the intact epithelial barrier, the central corneal epithelium has traditionally been debrided to a diameter of 8.0 to 9.0 mm to provide an effective adsorption of corneal stroma.
In pediatric CXL, the pain induced by epithelial debridement and consequent temporary visual loss make postoperative management more complicated. The risk of postoperative complications (eg, stromal haze 7 and infection 8 ) and the variable period of visual recovery (2 to 6 months) [9] [10] [11] represent other limitations to consider in pediatric treatments.
Recently, transepithelial CXL 12, 13 has been introduced, based on the use of a specially formulated ribofl avin solution. The theoretical basis for transepithelial CXL lies in the possibility of the penetration of a hydrophilic macromolecule such as ribofl avin through the corneal epithelium, thus avoiding K ABSTRACT PURPOSE: To report 18-month follow-up after transepithelial cross-linking (CXL) in young patients. 
METHODS:

PATIENTS AND METHODS
In this prospective, observational case series, 13 eyes from 13 patients (12 boys and 1 girl) with keratoconus (stage 2 or 3 according to Amsler-Krumeich classifi cation) were evaluated. Mean patient age was 14.4Ϯ3.7 years (range: 8 to 18 years). Patients with corneal scars or opacities and anterior segment pathology were excluded from the study. All treatments except 1 (an 8-year-old) were performed using topical anesthesia.
All experimental investigations reported herein were performed with informed consent and followed all guidelines for experimental investigation with human subjects required by the institutions with which both authors are affi liated. Corrected distance visual acuity (CDVA) analyzed as the logMAR value; spherical equivalent refraction; maximum keratometry (Kmax, the steepest meridian with its curvature expressed in diopters [D]); minimum keratometry (Kmin, the fl attest meridian with its curvature expressed in D); average keratometry (Kavg, the mean curvature between Kmax and Kmin); coma, spherical aberration, and higher order aberrations (HOAs) for a 5.0-mm pupil; and thinnest point were measured preoperatively and 1, 3, 6, 9, 12, and 18 months postoperatively by Sirius Scheimpfl ug camera (CSO, Florence, Italy). The Sirius software displays a series of indices describing the morphology of the cornea, which are useful in the diagnosis of keratoconus and its follow-up. The steepest point of the anterior surface (AKf-Apical KeratometryFRONT) and the steepest point of the posterior surface (AKb-Apical KeratometryBACK) were evaluated.
Endothelial cell density was assessed using a noncontact specular microscope (CSO), and anterior segment optical coherence tomography (Spectral OCT SLO; OPKO/OTI, Toronto, Canada) was performed to evaluate the demarcation line depth.
SURGICAL PROCEDURE
The enhanced ribofl avin solution was instilled 30 minutes before UVA exposure, with one drop being instilled every 2 minutes thereafter. The enhanced ribofl avin solution is an aqueous solution of 0.1% ribofl avin containing trometamol (Tris-hydroxymethyl aminomethane) and sodium EDTA as excipients and epithelial penetration enhancers. To reduce the risk of UV exposure of retroirideal eye structures, miosis was induced with pilocarpine 1.0% 30 minutes before the procedure. Thirty minutes before UV radiation, the cornea was anesthetized with single-dose anesthetic eyedrops (oxybuprocaine hydrochloride 0.2%), one drop every 4 minutes, repeated four times. All treatments were performed by the UV source (CBM X-linker VEGA, CSO) with the power set at 3.0 mW/cm 2 and a circular spot diameter of 8.0 mm in an outpatient setting. The cornea was irradiated with UVA for 30 minutes. During the irradiation, a blepharostat was applied and a homogeneous level of the enhanced ribofl avin solution was constantly maintained by adding one drop every 3 to 5 minutes. At the end of the procedure, all residue of the enhanced ribofl avin solution was rinsed away with a sterile physiologic salt solution. Immediately postoperatively, the treated eye was medicated with one drop of single-dose antibiotic-steroid association.
The cornea was examined with a slit lamp to assess the integrity of the epithelial layer, and the patient was given a prescription for single-dose antibiotic, one drop three times a day and sodium hyaluronate 0.15% with amino acids, one drop three times a day for 20 days.
STATISTICAL ANALYSIS
A paired Student t test was used to compare preand 12-and 18-month postoperative data. PϽ.05 was considered signifi cant. Table 1 shows refractive outcome. Corrected distance visual acuity improved throughout 18-month follow-up, with signifi cant increases noted at 12 and 18 months (PϽ.05). Spherical equivalent refraction did not change signifi cantly (PϾ.05) 12 and 18 months after CXL; the same was true for sphere and cylinder (PϾ.05).
RESULTS
All topographic derived data (Table 2) showed progressive statistically signifi cant worsening at 12-and 18-month follow-up (PϽ.05). 
DISCUSSION
In this study, transepithelial CXL did not halt the progression of keratoconus in patients younger than 18. In the literature and clinical practice, the progression of keratoconus is generally defi ned as an increase in the maximum K value by 1.00 D over 6, 12, or 24 months. 10, 11, 14 Our data show a statistically signifi cant worsening of all K readings that demonstrates the progression of keratoconus.
In younger patients, the progression of keratoconus Transepithelial CXL in Children/Buzzonetti & Petrocelli is generally fast and the risk of requiring keratoplasty 15 is high. Corneal collagen CXL with the use of ribofl avin and UVA irradiation is the latest technique being proposed for the stabilization of ectatic disorders such as keratoconus. The basic principle of CXL is the induction of cross-links in the corneal stroma, producing a stiffening effect and increasing corneal strength and stability. 3, 4 Caporossi et al 10 suggested that CXL is most indicated in young patients, especially those younger than 26 years with both clinical and instrumental documented evidence of keratoconus progression. The standard protocol includes, for safety purposes, a minimum corneal thickness of 400 μm and biomicroscopic evidence of clear cornea (absence of scars and accentuated Vogt striae) after epithelial removal, which is necessary for an effective CXL treatment. 16 Recently, some authors 17, 18 reported a signifi cant improvement in CDVA, corneal asymmetry, and aberrometric pattern after CXL in pediatric patients.
Transepithelial CXL is performed without the need for epithelial debridement. Baiocchi et al 19 observed that the human corneal epithelium complete with basement membrane naturally absorbs 30% to 33% of UVA radiation and with substantial concentrations of ribofl avin in the epithelium, it seems to block approximately 85% of the dose of UVA administered; the authors found that consequently this high epithelial absorption reduces the risk of endothelial toxicity of UVA, but gives rise to doubts about the effi cacy of transepithelial passage. Moreover, they reported that stromal concentrations of ribofl avin, one hundredth of those recorded in debrided corneal stroma, would greatly reduce production of singlet oxygen and limit cross-linking.
Some authors, 12, 13, 20 however, reported that the improvements in keratometry provided by transepithelial CXL appeared comparable to those published for standard CXL. Koppen et al 21 evaluated the effect of benzalkonium chloride-assisted transepithelial CXL in eyes with progressive keratoconus with minimum 6-month follow-up. They treated 53 eyes of 38 patients, mean patient age 24.02Ϯ7.29 years (range: 12 to 46 years). They observed a statistically signifi cant improvement in CDVA at 6 and 12 months, whereas Scheimpfl ug measurements of Kmax and pachymetry at the thinnest point showed statistically signifi cant progression throughout the study.
Our fi ndings show that in pediatric patients 18 months after treatment, CDVA signifi cantly improves in contrast to the worsening of topographic data. The corneal higher order aberrations evaluated demonstrated no change in coma and spherical aberration whereas higher order aberrations showed signifi cant worsening at 18 months. Filippello et al 13 suggested that anterior transepithelial CXL could be effective, at least in part, because the density of collagen fi bers in corneal stroma is higher in the anterior portion, where most of the collagen cross-links develop. The depth of the demarcation line, whose origin is not yet well known and differs from the value reported with the epithelial debridement of approximately 300 μm, 22 was measured to be approximately 105 μm 13, 20 from the epithelial surface, which could support this opinion.
The variability of our results appears high 18 months after transepithelial CXL. The small size sample, the interindividual differences, as well as the young age of the patients enrolled in this study may have an affect on the individual responses. Another possible limitation of the procedure could be the application of the blepharostat during the treatment; its removal in fact could avoid the ribofl avin meniscus that could mask the cross-linking effect. However, the poor cooperation of the majority of our patients did not allow the use of a ring-shaped silicone container, 13 the alternative to blepharostat, designed for ribofl avin refi ll, which resists the pressure of the eyelid and allows minimum lid adjustments. However, as rapid disease progression is usually observed in pediatric patients affected by keratoconus, the signifi cant improvement in CDVA appears meaningful. Additional follow-up will clarify the true progress of the aberrometric pattern. It is important to note that in patients affected by keratoconus, CDVA could improve simply because with repeated measurements the refraction could shift due to the subjective and objective effect of irregular astigmatism. However, in this series of patients, the same ophthalmologist (L.B.) performed all visual acuity measurements, thereby reducing the variability of the CDVA examination.
Transepithelial CXL is a safe and comfortable procedure for pediatric patients but its effectiveness remains doubtful. To date, this technique does not appear to stop the progression of keratoconus, and our fi ndings, similar to those reported by Koppen et al 21 although for a different patient age group and transepithelial CXL technique, seem to show a limited effect. Further studies, a larger sample of patients, and longer follow-up are needed to evaluate the true effi cacy of transepithelial CXL. This procedure could be considered complementary to traditional CXL, especially for less cooperative patients for whom epithelial debridement may be distressing as well as for eyes with a minimum preoperative corneal thickness Ͻ400 μm.
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